ストックスクリーナーアプリを入手
1.06
0.95%
0.01
アフターアワーズ：
1.05
-0.01
-0.94%
前日終値:
$1.05
開ける：
$1.04
24時間の取引高:
60,507
Relative Volume:
0.15
時価総額：
$5.52M
収益：
-
当期純損益:
$-18.68M
株価収益率:
-0.1433
EPS:
-7.3948
ネットキャッシュフロー:
$-15.70M
1週間 パフォーマンス:
-1.85%
1か月 パフォーマンス:
-25.35%
6か月 パフォーマンス:
-80.52%
1年 パフォーマンス:
-93.46%
1日の値動き範囲:
$1.02
$1.0929
1週間の範囲:
$1.0016
$1.0929
52週間の値動き範囲:
$0.9523
$19.80
Fibrobiologics Inc Stock (FBLG) Company Profile
Compare FBLG vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
FBLG
Fibrobiologics Inc
|
1.06 | 5.47M | 0 | -18.68M | -15.70M | -7.3948 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Fibrobiologics Inc Stock (FBLG) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-12 | 開始されました | Rodman & Renshaw | Buy |
| 2024-10-30 | 開始されました | H.C. Wainwright | Buy |
| 2024-09-24 | 開始されました | Maxim Group | Buy |
Fibrobiologics Inc (FBLG) 最新ニュース
FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting - Sahm
Fibroblast cell therapy avoided psoriasis relapse in FibroBiologics mouse study - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
FBLG Stock Price, Quote & Chart | FIBROBIOLOGICS INC (NASDAQ:FBLG) - ChartMill
FBLG Stock Chart | FIBROBIOLOGICS INC (NASDAQ:FBLG) - ChartMill
Exclusive: FibroBiologics moves forward with human trial for diabetic foot ulcer therapy - MSN
FibroBiologics files patent for oral fibroblast delivery system - Investing.com UK
FibroBiologics files patent for oral fibroblast delivery system By Investing.com - Investing.com Australia
New oral cell therapy platform aimed at gut diseases from IBS to Crohn's - Stock Titan
Exclusive: FibroBiologics targets 2026 data readout after trial progress for diabetic foot ulcer study - MSN
TradingKey - TradingKey
Fibrobiologics explores use of fibroblast platform for hantavirus - BioWorld News
FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus - GlobeNewswire
Severe Hantavirus syndrome lacks drugs, FibroBiologics tests fibroblast therapy - Stock Titan
FibroBiologics | 424B5: Prospectus - Moomoo
FBLG | FibroBiologics, Inc. Common Stock Executive Compensation - Quiver Quantitative
FibroBiologics, Inc. Files Form 8-K Announcing Material Definitive Agreement and Company Details - Minichart
FibroBiologics Expands At-The-Market Equity Offering Capacity - TipRanks
FibroBiologics Grants Stock Options to Key Executives - The Globe and Mail
FibroBiologics (NASDAQ: FBLG) expands $7.5M at-the-market stock offering - Stock Titan
FibroBiologics begins patient enrollment for diabetic foot ulcer trial By Investing.com - Investing.com Australia
FibroBiologics (NASDAQ: FBLG) expands ATM capacity to $7.5M under S-3 - Stock Titan
EXCLUSIVE: FibroBiologics Targets 2026 Data Readout After Trial Progress For Diabetic Foot Ulcer Study - Sahm
FibroBiologics | DEFA14A: Others - Moomoo
FibroBiologics begins patient enrollment for diabetic foot ulcer trial - Investing.com
FibroBiologics CEO Issues Letter to Shareholders - markets.businessinsider.com
33 million people have diabetic foot ulcers. FibroBiologics starts a trial - Stock Titan
FibroBiologics grants stock options to CEO Pete O’Heeron and CFO Jason D. Davis - TradingView
[8-K] FibroBiologics, Inc. Reports Material Event - Stock Titan
FibroBiologics (FBLG) seeks approval for warrant shares and 2026 equity incentive plan - Stock Titan
FibroBiologics reports preclinical burn wound treatment results _newTouch_By Investing.com - Investing.com South Africa
FibroBiologics | 4: Statement of changes in beneficial ownership of securities-Officer Davis Jason - Moomoo
FibroBiologics | 4: Statement of changes in beneficial ownership of securities-Officer GARCIA RUBEN A - Moomoo
FibroBiologics | 4: Statement of changes in beneficial ownership of securities-Officer O'HEERON PETE - Moomoo
FibroBiologics reports preclinical burn wound treatment results By Investing.com - Investing.com South Africa
Fibrobiologics Inc (FBLG) 財務データ
収益
当期純利益
現金流量
EPS
Fibrobiologics Inc (FBLG) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| O'HEERON PETE | CHIEF EXECUTIVE OFFICER |
Mar 03 '26 |
Buy |
0.41 |
18,200 |
7,373 |
5,942,275 |
| O'HEERON PETE | CHIEF EXECUTIVE OFFICER |
Mar 02 '26 |
Buy |
0.35 |
17,428 |
6,152 |
5,924,075 |
| O'HEERON PETE | CHIEF EXECUTIVE OFFICER |
Mar 04 '26 |
Buy |
0.38 |
15,872 |
6,006 |
5,958,147 |
| Davis Jason | Chief Financial Officer |
Mar 02 '26 |
Buy |
0.41 |
70,000 |
28,973 |
70,000 |
| GARCIA RUBEN A | General Counsel |
Feb 27 '26 |
Buy |
0.33 |
40,000 |
13,056 |
180,000 |
| GARCIA RUBEN A | General Counsel |
Dec 11 '25 |
Buy |
0.34 |
140,000 |
47,600 |
140,000 |
| Khoja Hamid | Chief Scientific Officer |
May 27 '25 |
Buy |
0.84 |
20,000 |
16,800 |
31,250 |
0.98%
0.12%
大文字化:
|
ボリューム (24 時間):